PSYCHIATRY AND CLINICAL NEUROSCIENCES is a leading journal in the fields of psychiatry and clinical neurology, published by Wiley. With a commendable impact factor and a position within the prestigious Q1 quartile across multiple relevant categories—including Medicine (Miscellaneous), Neurology, and Psychiatry and Mental Health—this journal stands out for its rigorous peer-reviewed content that addresses critical issues in mental health and neurological disorders. Established in 1933, the journal has a rich history of contributing impactful research that guides both clinical practice and academic inquiry. Although it is not an open-access journal, its high relevance is underscored by its Scopus rankings, with notable percentiles in Psychiatry and Neurology, making it a vital resource for researchers, clinicians, and students looking to stay abreast of the latest advancements. Located in the United Kingdom, PSYCHIATRY AND CLINICAL NEUROSCIENCES aims to bridge the gap between theory and practical application, fostering a comprehensive understanding of the complex interplay between mental health and neurological conditions.

Behavior Therapy, published by Elsevier Inc, is a premier journal in the field of Clinical Psychology, recognized for its significant contributions to the empirical understanding and practical application of behavior therapy interventions. With an impressive impact factor ranking it in the Q1 quartile of Clinical Psychology as of 2023, and a commendable position in the 87th percentile among its peers, this journal serves as a vital resource for researchers, practitioners, and students alike. Since its inception in 1970, Behavior Therapy has dedicated itself to publishing high-quality original research, comprehensive reviews, and insightful case studies that cover the latest advancements in treatment modalities and behavioral interventions. The journal is committed to fostering a deeper understanding of psychological processes and therapeutic techniques, making it an essential platform for innovative ideas and effective practices in the realm of behavior therapy.

PSYCHIATRIC GENETICS, published by LIPPINCOTT WILLIAMS & WILKINS, is a pivotal journal dedicated to the interdisciplinary study of genetic factors in psychiatric disorders, bridging the fields of genetics, psychiatry, and neuroscience. With a commitment to advancing research from its inception in 1990 and continuing through 2024, the journal provides a platform for innovative studies and findings that explore the genetic underpinnings of mental health. Although not currently an Open Access publication, it reaches a wide audience concerned with the complex interplay between genetics and psychiatric conditions, contributing to its Q3 and Q2 quartile rankings across multiple relevant categories in 2023. The importance of this journal cannot be understated; it serves as a crucial resource for researchers, clinicians, and students eager to uncover insights that could lead to more effective interventions and treatments in the realm of mental health.

Cognitive Neuropsychiatry is a distinguished academic journal published by Routledge Journals, Taylor & Francis Ltd, dedicated to the intersection of cognitive neuroscience and psychiatry. With a strong commitment to advancing knowledge in these rapidly evolving fields, this journal provides a platform for high-quality, peer-reviewed research that explores cognitive processes underlying psychiatric disorders. Aiming to bridge gaps between neuroscience and clinical practice, it serves as an essential resource for researchers, professionals, and students alike. As evidenced by its performance metrics, the journal ranks in the Q2 quartile for Psychiatry and Mental Health, and Q3 for Cognitive Neuroscience, showcasing its relevance and growing impact, particularly among a competitive audience. While it does not currently offer open access options, Cognitive Neuropsychiatry remains a vital outlet for disseminating impactful findings, offering insights that shape contemporary psychiatric understanding and interventions.

PSYCHOLOGICAL MEDICINE is a leading journal in the field of psychiatry and psychology, published by Cambridge University Press. With its ISSN 0033-2917 and E-ISSN 1469-8978, this journal has firmly established itself as a premier platform for cutting-edge research since its inception in 1970. It consistently ranks in the top quartile for both Applied Psychology and Psychiatry and Mental Health, reflecting its exceptional impact in the field, with a 2023 Scopus ranking of #36 out of 567 in Psychiatry and Mental Health, and #21 out of 249 in Applied Psychology. The journal aims to publish comprehensive studies that explore the interplay between psychological phenomena and medical health, contributing vital insights that advance both theoretical understanding and clinical practice. Although it is not an Open Access journal, PSYCHOLOGICAL MEDICINE remains a vital resource for researchers, professionals, and students committed to the scientific investigation of mental health issues.

ACTAS ESPANOLAS DE PSIQUIATRIA, published by the renowned JUAN JOSE LOPEZ-IBOR FOUNDATION, serves as a vital resource in the field of psychiatry and mental health, particularly within the Spanish-speaking academic community. With its ISSN 1139-9287 and E-ISSN 1578-2735, this journal has been a critical platform for disseminating high-quality research since its inception in 1996 and continues to contribute valuable insights until 2024. As a recognized journal in the Q3 category of psychiatry and mental health, it ranks 387 out of 567 in Scopus, placing it within the 31st percentile, thereby indicating a growing influence among its peers. The journal’s open access options enhance its accessibility, encouraging a broader readership to engage with contemporary research issues in mental health. Researchers, professionals, and students alike will find ACTAS ESPANOLAS DE PSIQUIATRIA essential for staying informed on the latest developments and innovations in psychiatric practice and research.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a leading peer-reviewed journal that serves the interdisciplinary field of neuropsychopharmacology and biological psychiatry. With an impressive impact factor in the first quartile of both Biological Psychiatry and Pharmacology categories, this journal provides a critical platform for the dissemination of cutting-edge research and innovative therapeutic approaches. Covering a broad range of topics from the molecular mechanisms underlying psychiatric disorders to advanced pharmacological interventions, it aims to foster scientific dialogue among researchers, clinicians, and students alike. The journal has been at the forefront of scientific inquiry since its inception in 1982 and continues to evolve, adapting to the ever-changing landscape of neuroscience and mental health research. With its focus on high-quality articles and a commitment to advancing the understanding of neuropsychopharmacology, this journal is essential for anyone interested in the complexities of brain function and mental health.

The Journal of Dual Diagnosis, published by Routledge Journals, Taylor & Francis Ltd, is a leading interdisciplinary platform dedicated to the critical study of co-occurring mental health and substance use disorders. With its ISSN 1550-4263 and E-ISSN 1550-4271, this esteemed journal has been at the forefront of advancing research and clinical practice since its inception in 2004, and continues to serve as a vital resource until 2024. Ranked in the second quartile (Q2) in Psychiatry and Mental Health and positioned at the 64th percentile in the Scopus rankings, it emphasizes the importance of integrating care across various domains of health. Although not open access, it offers a wealth of peer-reviewed articles, case studies, and reviews suitable for researchers, practitioners, and students alike, aiming to enhance our understanding and treatment of dual diagnosis. The journal's commitment to addressing the complexities of dual disorders not only informs research but also shapes policy and clinical guidelines, making it an essential read for anyone involved in these critical areas of mental health.

JOURNAL OF PSYCHOPHARMACOLOGY, published by SAGE Publications Ltd, is a leading peer-reviewed journal that explores the intricate dynamics of pharmacological interventions in mental health and psychiatry. With an ISSN of 0269-8811 and an E-ISSN of 1461-7285, this esteemed journal has established its reputation in the field since its inception in 1987, converging research excellence into 2024. Recognized as a Q1 journal in various categories including Medicine (miscellaneous), Pharmacology, and Psychiatry and Mental Health, it ranks impressively within the top percentile in Scopus, standing at #64 out of 567 in Psychiatry and Mental Health, and #31 out of 272 in Medical Pharmacology. The journal serves as a vital resource for researchers, professionals, and students, providing insightful articles that advance the understanding of psychopharmacological effects and innovations. Although it does not offer open access, the journal's extensive research and impactful findings make it essential reading for anyone engaged in the field. For those seeking to stay at the forefront of psychopharmacology, the JOURNAL OF PSYCHOPHARMACOLOGY is an invaluable asset.

HEADACHE is a premier academic journal dedicated to advancing the study of headache disorders through innovative research and clinical insights. Published by WILEY, this influential journal has been serving the neurology community since its inception in 1961 and is recognized as a leader in its field, boasting an impressive Q1 ranking in both Neurology and Neurology (clinical) categories for 2023. With a robust Scopus ranking of #48 in clinical neurology and #26 in neuroscience, HEADACHE consistently publishes high-quality research that contributes to the understanding and treatment of headache disorders worldwide. Although it does not offer open access options, the journal remains accessible to a wide audience through various institutional subscriptions. It aims to provide a platform for researchers, healthcare professionals, and students to exchange ideas and develop new strategies for headache management, making it an essential resource for those dedicated to improving patient outcomes in this challenging area of healthcare.